Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Cannabidiol,Cannabichromene,Tetrahydrocannabinol
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
ZYUS Life Sciences Receives NOC from Health Canada for Proof-of-Concept Trial
Details : Trichomylin softgels, a first-in-class drug product candidate formulated with a proprietary fixed-dose cannabinoid combination, has been specifically designed for the management of chronic pain.
Product Name : Trichomylin
Product Type : Controlled Substance
Upfront Cash : Inapplicable
July 30, 2024
Lead Product(s) : Cannabidiol,Cannabichromene,Tetrahydrocannabinol
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cyclophosphamide
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Zydus Lifesciences gets USFDA Nod for Generic Cancer Treatment Capsules
Details : Cyclophosphamide-Generic is a DNA cross-linker, small molecule, cytotoxic drug candidate, which is currently being evaluated for the treatment of lymphoma.
Product Name : Cyclophosphamide-Generic
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
December 14, 2023
Lead Product(s) : Cyclophosphamide
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cannabidiol,Cannabichromene,Tetrahydrocannabinol
Therapeutic Area : Musculoskeletal
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Trichomylin softgels, a first-in-class drug product candidate formulated with a proprietary fixed-dose cannabinoid combination, has been specifically designed for the management of chronic pain.
Product Name : Trichomylin
Product Type : Controlled Substance
Upfront Cash : Inapplicable
November 21, 2023
Lead Product(s) : Cannabidiol,Cannabichromene,Tetrahydrocannabinol
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ivabradine Hydrochloride
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Zydus Lifesciences Gets USFDA Nod for Generic Heart Failure Treatment Drug
Details : USFDA approved generic version of Ivabradine, is a small molecule oral blocker of HCN channels, which is indicated to reduce the risk of hospitalisation for worsening heart failure in adult patients with stable, symptomatic chronic heart failure with cer...
Product Name : Ivabradine-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 12, 2023
Lead Product(s) : Ivabradine Hydrochloride
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cannabidiol
Therapeutic Area : Musculoskeletal
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
ZYUS Announces Database Lock for its Phase 1 First-in-Human Clinical Trial
Details : Trichomylin® softgels, is a proprietary novel fixed-dose cannabinoid formulation developed by ZYUS to alleviate chronic pain and has the potential to be a safe and effective alternative to opioids – without the devasting addictive qualities
Product Name : Trichomylin
Product Type : Controlled Substance
Upfront Cash : Inapplicable
November 15, 2022
Lead Product(s) : Cannabidiol
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cannabinoid,Tetrahydrocannabinol
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : A new THC-dominant medical cannabinoid formulation, Zylem™ 20:1, for direct sales and distribution to registered medical patients across Canada as a standard of care and expand the potential of protein-based formulations in pursuit of a transformationa...
Product Name : Zylem
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 17, 2021
Lead Product(s) : Cannabinoid,Tetrahydrocannabinol
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cannabidiol
Therapeutic Area : Musculoskeletal
Study Phase : Phase I
Sponsor : Aureuspharma
Deal Size : Undisclosed
Deal Type : Partnership
Details : Under the agreement, ZYUS’ cannabinoid formulations are expected to hit the Portuguese market as early as the second half of 2021. It's lead drug product candidate, Trichomylin® for pain management in a limited number of patients with osteoarthritis.
Product Name : Trichomylin
Product Type : Controlled Substance
Upfront Cash : Undisclosed
May 27, 2021
Lead Product(s) : Cannabidiol
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase I
Sponsor : Aureuspharma
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Cannabidiol
Therapeutic Area : Musculoskeletal
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
ZYUS Launches HOPE (Human Osteoarthritis Pain Evaluation) Phase 1 First in Human Clinical Trials
Details : ZYUS Life Sciences will be launching a first-in-human (FIH) clinical trial on the safety, tolerability and efficacy of its lead drug product candidate, Trichomylin®, through its wholly owned subsidiary, ZYUS Life Sciences Australia Pty. Ltd.
Product Name : Trichomylin
Product Type : Controlled Substance
Upfront Cash : Inapplicable
April 19, 2021
Lead Product(s) : Cannabidiol
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Discovery
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
ZYUS Announces Positive Milestone in Plant-Based COVID-19 Vaccine Antigen Production
Details : Preliminary research results from ZYUS Life Sciences show that plant-based antigens are reactive to anti-COVID-19 antibodies and potentially offer immunity from COVID-19.
Product Name : Undisclosed
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
July 15, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Discovery
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Psychiatry/Psychology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Pre-clinical study seeks to determine the impact of cannabis derivatives on mental health conditions.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
July 01, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
